ダウンロード数: 177
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
68_9_295.pdf | 674.01 kB | Adobe PDF | 見る/開く |
タイトル: | 重症筋無力症発症後にペムブロリズマブ再投与を行った尿路上皮癌の1例 |
その他のタイトル: | Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report |
著者: | 黒川, 真行 清水, 浩介 北林, 亮太 小河, 考輔 岡田, 能幸 久保, 研一郎 山口, 大介 大久保, 和俊 |
著者名の別形: | KUROKAWA, Masayuki SHIMIZU, Kosuke KITABAYASHI, Ryota OGAWA, Kosuke OKADA, Yoshiyuki KUBO, Kenichiro YAMAGUCHI, Daisuke OKUBO, Kazutoshi |
キーワード: | Urothelial carcinoma Pembrolizumab Myasthenia gravis Renal pelvic cancer Readministration |
発行日: | 30-Sep-2022 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 68 |
号: | 9 |
開始ページ: | 295 |
終了ページ: | 300 |
抄録: | Immune checkpoint inhibitors (ICIs) provide excellent benefits to the treatment of various cancer types, including urothelial carcinoma. Conversely, they can cause immune-related adverse events (irAEs), and some of them are severe or fatal. Furthermore, evidence on the safety and effectiveness of the readministration of ICIs after the occurrence of irAEs is limited. In this case report, a 78-year-old man who suffered from metastatic right renal pelvic cancer was treated with pembrolizumab. He had a partial response to pembrolizumab, but he developed grade 3 myasthenia gravis. The myasthenia gravis symptoms were immediately relieved by corticosteroids and intravenous immunoglobulin therapy. When the disease rapidly progressed, he was treated again with pembrolizumab. After 5 days, a chest radiograph showed shrinkage of pulmonary metastases. Unfortunately, he died of multiple brain infarctions 7 days after the readministration. We report this case with a literature review on the efficacy and safety of the readministration of ICIs after the occurrence irAEs including myasthenia gravis. |
記述: | 本論文の要旨は第248回日本泌尿器科学会関西地方会にて発表した. |
著作権等: | 許諾条件により本文は2023-10-01に公開 |
DOI: | 10.14989/ActaUrolJap_68_9_295 |
URI: | http://hdl.handle.net/2433/276608 |
PubMed ID: | 36199208 |
出現コレクション: | Vol.68 No.9 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。